Drug Trial Radar · NCT02318277
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Jan 5, 2015
Primary completion
Aug 28, 2019
Study completion Oct 16, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Dec 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.
Conditions
- Solid Tumors
- Head and Neck Cancer
- Lung Cancer
- UC (Urothelial Cancer)
Interventions
MEDI4736Drug
MEDI4736 administered intravenously (IV) every two weeks (q2w)
INCB024360Drug
INCB024360: Oral daily dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)Time frame: Duration of study treatment and up to 90 days after the last dose [approximately 3 years]
- Phase 2: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Measured every 8 weeks for duration of study treatment [approximately 12 months]
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site not named
San Francisco, California
Site not named
Denver, Colorado
Site not named
Miami, Florida
Site not named
Port Saint Lucie, Florida
Site not named
Sarasota, Florida
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Louisville, Kentucky
Site not named
Durham, North Carolina
Site not named
Huntersville, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Dallas, Texas
Site not named
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.